Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pharmaceutical consultation, Pharmaceutical consultation and follow-up.
- Who it may be relevant to
- Registry conditions: Neoplasm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Impact of the Clinical Pharmacist in the Initiation and Follow-up of Oral Therapies in Oncology.
Overview
The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the hospital and the patient's home pharmacy, so that the patient can continue to receive care at home. It is also essential that the hospital pharmacy and the patient's local pharmacy work together within a reasonable timeframe. This will help improve patient care and treatment follow-up, detect any undesirable effects and optimize their management.. The aim of this prospective interventional study is to measure the benefits of pharmaceutical monitoring in healthcare institutions at the initiation of oral therapy on patient compliance, side-effect management and adherence, in comparison with patients without this monitoring. The primary endpoint is compliance with the Girerd questionnaire.
Interventions
- Procedure Pharmaceutical consultation
The pharmaceutical interview is a structured way of carrying out an optimized medication review with the patient. This interview takes place at the time of the first prescription of oral anti-cancer treatment. - Procedure Pharmaceutical consultation and follow-up
After the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book.
Primary outcome measures
- Observance [Time frame: 3 months and 6 months after treatment initiation]
Eligibility criteria
Inclusion criteria
- Patient suffering from an oncological pathology (excluding hematological malignancies)
- Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments).
- Patient who has not yet started treatment or who has started treatment less than 30 days
- Patient with continuation of oral therapy dispensed in pharmacies
Exclusion criteria
- Patients suffering from hematological malignancies
- Patient living in an institution or hospital
- Patient under treatment for more than 30 days
- Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment)
- Patient whose treatment after initiation is not dispensed in a pharmacy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
France · 1 center
- Polyclinique Lyon Nord — Rillieux-la-Pape
Identifiers
NCT: NCT06980012 · 2024-18-PLN